The history of metformin-associated lactic acidosis (MALA) is rooted in the earlier experience with phenformin, another biguanide treatment for type 2 diabetes that was removed from the market owing to a clear causal association with cases of lactic acidosis (LA).
Although metformin is less problematic in this regard, metformin can and does induce LA, and under the right circumstances it continues to present a potential risk to patients. Recent liberalization of the prescribing guidelines in the USA and European Union specifically regarding use in more advanced stages of chronic kidney disease (CKD) have led to renewed interest in the topic of MALA, and this issue of Diabetes Obesity Metabolism presents two timely articles on the topic, by Lalau et al. 1 and Connelly et al. 2 Lalau et al. 1 outline a new way of thinking regarding the extremely rare, but often serious and potentially fatal, condition of MALA. They present a thoughtful analysis of existing MALA data and propose a more precise framework and nomenclature for categorizing LA with regard to whether metformin is clearly implicated causally, or is more of an "innocent bystander". Specifically, the authors propose a framework, primarily based on the presence of any other underlying condition that can cause LA, as well as a metformin measurement, within the proposed "umbrella" category of "lactic acidosis in metformin therapy" (LAMT) as follows. (1 While a more precise categorization paradigm may provide useful guidance to clinicians when dealing with suspected cases of MALA, the authors suggest that metformin does not play a contributing role in cases in which any other condition could be attributed to the LA event, and conclude that MULA "is probably by far the most common."
The authors do not provide new data to justify such a conclusion, and this conclusion does not incorporate the additive and perhaps Thus, for reasons stated we believe that, in the vast majority of cases, we do not have the ability to exclude the known ability of metformin to increase LA risk. Our concern is that, while attempting to add more precision to the terms used to define LA in the presence of metformin use, a binary classification system that would discount the contribution of metformin based on a cross-sectional assessment of the patient would be inappropriate from a pharmacovigilance perspective as it will probably lead to underreporting of metformin's association with LA. We refer the reader to a recent report by Boucaud-Maitre et al. 6 metformin plasma exposure and efficacy is not that simple. There is increasing evidence that a substantial contribution to the glycaemic effect of metformin is mediated through the intestine rather than primarily through systemic exposure. [9] [10] [11] [12] [13] Given that the bioavailability of metformin increases with decreasing dose, 14 it is unlikely that the low doses of metformin required to maintain acceptable plasma concentrations would deliver sufficient metformin to the intestine to leverage the gut-based mechanisms of action. 
